{
    "nct_id": "NCT03830164",
    "official_title": "Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate\n* Previous radiation therapy (any form) with curative intent for prostate cancer\n* Erectile dysfunction, as determined by an International Index of Erectile Function (IIEF)-5 score of < 22\n* Normal testosterone (including men on testosterone replacement), defined as testosterone > 150 ng/dl at the time of screening\n* Karnofsky Performance Status (KPS) >= 70, or Eastern Cooperative Oncology Group (ECOG) 0-2\n* Patients may be taking an HMG-coA-reductase inhibitor\n* Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 X upper limits of normal (ULN)\n* Creatinine kinase < 5 times ULN\n* Normal renal function is defined as creatinine clearance >= 30 ml/min via the Cockcroft Gault formula\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* No androgen deprivation therapy within the past 12 months\n* No contraindication to an HMG-coA-reductase inhibitor, vitamin E or pentoxifylline\n* Not currently taking cyclosporine, the human immunodeficiency virus (HIV) protease inhibitors, hepatitis C protease inhibitors, gemfibrozil, other fibrates, clarithromycin, itraconazole or strong inhibitors of CYP3A4\n* No recent cerebral or retinal hemorrhage that in the opinion of the treating physician would make PAVE unsafe (within 6 months)\n* No current chemotherapy during study participation\n* No active liver or muscle disease that in the opinion of the treating physician would make PAVE unsafe\n* No prior radical prostatectomy, cystoprostatectomy, abdominoperineal resection or retroperitoneal lymph node dissection\n* Not currently taking a 5PDE inhibitor nor have used one within 30 days of enrolling in the study\n* No recent deep venous thrombosis, myocardial infarction or pulmonary embolism (within 6 months) requiring continued anticoagulation other than aspirin (acetylsalicylic acid [ASA])\n* No cardiac arrhythmias or artificial heart valves requiring anticoagulation other than ASA\n* No concurrent drugs with anti-platelet therapy properties (e.g., P2Y12 inhibitors, non-steroidal anti-inflammatory agents, selective serotonin reuptake inhibitors) other than low dose ASA (81 mg/d)\n* Not currently taking high dose statin therapy, defined as rosuvastatin > 10 mg/d or atorvastatin > 40 mg/d\n* Not currently taking theophylline\n* No history of active peptic ulcer disease in the past 6 months\n* No history of intolerance to pentoxifylline or methylxanthines such as caffeine, theophylline and theobromine that in the opinion of the treating physician would make PAVE unsafe\n* No concurrent use of CYP1A2 inhibitors (e.g., ciprofloxacin), ketorolac, or vitamin K antagonists (e.g. warfarin)",
    "miscellaneous_criteria": ""
}